Thanks for your reply. I do not immediately see why insurance coverage for treble damages in a patent infringement is different from insurance coverage for any kind of punitive damage.
Moreover, we should not automatically assume that Teva’s insurance policy for at-risk launches does in fact cover treble damages. Insofar as the awarding of treble damages is very rare (I do not know of a single case where it was done in drug-related litigation), it may be that Teva is satisfied with having insurance coverage for ordinary damages only.
Market Data 
Markets 
AI
